Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 54, 2019 - Issue 4
Submit an article Journal homepage
2,018
Views
42
CrossRef citations to date
0
Altmetric
Review

Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis

Davide Giuseppe RibaldoneDepartment of Surgical Sciences, University of Turin, Turin, Italy; Correspondence[email protected]
,
Rinaldo PellicanoMolinette Hospital, Unit of Gastroenterology, Turin, Italy;
,
Marta VerneroFirst Department of Internal Medicine, IRCCS Policlinico San Matteo University of Pavia, Pavia, Italy;
,
Gian Paolo CavigliaDepartment of Medical Sciences, University of Turin, Turin, ItalyORCID Iconhttp://orcid.org/0000-0002-0529-9481
ORCID Icon,
Giorgio Maria SaraccoDepartment of Medical Sciences, University of Turin, Turin, Italy
,
Mario MorinoDepartment of Surgical Sciences, University of Turin, Turin, Italy;
&
Marco AstegianoMolinette Hospital, Unit of Gastroenterology, Turin, Italy;
show all
Pages 407-413 | Received 06 Feb 2019, Accepted 14 Mar 2019, Published online: 04 Apr 2019

References

  • Peyrin-Biroulet L, Lémann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:870–879.
  • Actis GC, Pellicano R, Ribaldone DG. A concise history of thiopurines for inflammatory bowel disease: from anecdotal reporting to treat-to-target algorithms. Rev Recent Clin Trials. 2019;14:4–9.
  • Hirten RP, Iacucci M, Shah S, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol. 2018;16:1374–1384.
  • Afzali A, Chiorean M. Combination of biologic agents in the management of severe refractory Crohn’s disease: a case report of concomitant treatment with vedolizumab and adalimumab. Am J Gastroenterol. 2016;111:S823–S824.
  • Fischer S, Rath T, Geppert C-I, et al. Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory ulcerative colitis. Am J Gastroenterol. 2017;112:1621–1623.
  • Roblin X, Paul S, Ben-Horin S. Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy. J Crohns Colitis. 2018;12:379–380.
  • Buer LCT, Høivik ML, Warren DJ, et al. Combining anti-TNF-α and vedolizumab in the treatment of inflammatory bowel disease: a case series. Inflamm Bowel Dis. 2018;24:997–1004.
  • Mao EJ, Lewin S, Terdiman JP, et al. Safety of dual biological therapy in Crohn's disease: a case series of vedolizumab in combination with other biologics. BMJ Open Gastroenterol. 2018;5:e000243.
  • Huff-Hardy K, Bedair M, Vazquez R, et al. Efficacy of combination vedolizumab and ustekinumab for refractory Crohnʼs disease. Inflamm Bowel Dis. 2017;23:E49.
  • Liu EY, Loomes DE. Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn’s disease. Case Rep Med. 2017;2017:1–2.
  • Côté-Daigneault J, Bouin M, Lahaie R, et al. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3:419–428.
  • Ribaldone D, Pellicano R, Actis G, et al. Pathogenesis of inflammatory bowel disease: basic science in the light of real-world epidemiology. Gastrointest Disord. 2018;1:129–146.
  • Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870–1880.
  • Yzet C, Dupas J-L, Fumery M. Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease. Am J Gastroenterol. 2016;111:748–749.
  • Høivik ML, Moum B, Solberg IC, et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013;62:368–375.
  • Eriksson C, Marsal J, Bergemalm D, et al. Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scand J Gastroenterol. 2017;52:722–729.
  • Rutgeerts PJ. Review article: the limitations of corticosteroid therapy in Crohn’s disease. Aliment Pharmacol Ther. 2001;15:1515–1525.
  • Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2017;15:25–36.e27.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.